Experimental HCV Drugs
Experimental HCV Drugs
Coverage of the 2016 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Friday, 26 February 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 Conference on Retroviruses and Opportunistic infections (CROI 2016), February 22-25, 2016, in Boston.
HIVandHepatitis.com coverage by topic
2/26/16
Daclatasvir Plus Asunaprevir Cures Most Genotype 1b Chinese Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 23 February 2016 00:00
- Written by Bristol-Myers Squibb
An interferon- and ribavirin-free dual combination of Bristol-Myers Squibb's hepatitis C virus (HCV) NS5A inhibitor daclatasvir (Daklinza) and HCV protease inhibitor asunaprevir (Sunvepra) produced sustained response in more than 90% of genotype 1b chronic hepatitis C patients in China, researchers reported at the 25th Conference or the Asian Pacific Association for the Study of the Liver this week in Tokyo.
FDA Approves Zepatier (Grazoprevir/Elbasvir) for Hepatitis C Genotypes 1 and 4
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 28 January 2016 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) this week announced its approval of Merck's Zepatier -- a once-daily coformulation containing the hepatitis C virus (HCV) protease inhibitor grazoprevir and NS5A inhibitor elbasvir -- for the treatment of HCV genotypes 1 and 4. In several Phase 3 studies grazoprevir/elbasvir taken for 12 weeks demonstrated cure rates exceeding 90% for various groups including people with liver cirrhosis, HIV/HCV coinfected patients, and people who inject drugs.
AASLD 2015: MiR-122 Inhibitor RG-101 Suppresses Hepatitis C Virus with Single Dose
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 12 February 2016 00:00
- Written by Liz Highleyman
A single injection of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, reduced hepatitis C virus (HCV) levels by more than 4 log in people with HCV genotypes 1, 3, and 4, and 21% of treated patients still had undetectable virus levels 28 weeks after dosing, according to research presented at the AASLD Liver Meeting in November.
AbbVie Opens Global Phase 3 Studies of ABT-493/ABT-530 Hepatitis C Regimen
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 21 January 2016 00:00
- Written by AbbVie
AbbVie has started enrollment of a projected 1600 participants in 6 new international Phase 3 clinical trials evaluating a once-daily regimen of its investigational NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 for people with hepatitis C virus (HCV) genotypes 1 through 6, the company recently announced.
More Articles...
- AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate
- AASLD 2015: Grazoprevir/ Elbasvir Cures More than 90% of People with HIV/HCV Coinfection
- AASLD 2015: Intensification with Sofosbuvir Permits Cure after Previous HCV Treatment Failure
- AASLD 2015: Sofosbuvir/ Ledipasvir + Vedroprevir Cures 96% of Cirrhotic Genotype 1 Patients
Web Design and Development by